GENFIT (GNFT) Stock Price, News & Analysis

Company Overview

Genfit is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies and diagnostics for serious metabolic and inflammatory liver diseases. Founded and headquartered in Lille, France, the company has concentrated its efforts on nonalcoholic steatohepatitis (NASH), an area of significant unmet medical need. By combining expertise in molecular biology, chemistry and medical imaging, Genfit aims to deliver products that can both treat disease and improve diagnosis and monitoring of liver conditions.

The company’s lead therapeutic candidate, elafibranor (GFT505), is a first-in-class, dual PPAR alpha/delta agonist designed to address the underlying metabolic and inflammatory processes that drive NASH. Elafibranor has completed multiple Phase II and Phase III clinical studies assessing its efficacy and safety in patients with NASH, including those at risk for progression to fibrosis and cirrhosis. Genfit continues to explore additional indications and combination strategies to broaden the potential applicability of its pipeline assets.

In parallel with its therapeutic programs, Genfit has developed proprietary diagnostic technologies to support the noninvasive assessment of liver health. Through a combination of imaging biomarkers and blood-based tests, the company seeks to provide physicians with tools for early detection, staging and monitoring of liver disease progression. Genfit’s diagnostics platform is designed to complement its drug development efforts and may be applied across diverse patient populations.

Genfit operates in Europe and the United States, collaborating with clinical sites, academic institutions and industry partners to advance its research. The company is led by an experienced management team with backgrounds in biotechnology, pharmaceutical development and medical research. Genfit continues to pursue regulatory interactions and strategic collaborations to bring its therapies and diagnostics to patients worldwide.

Key Stats

• Today's Range: $4.85 to $4.85
• 50-Day Range: $3.86 to $4.85
• 52-Week Range: $3.41 to $4.93
• Volume: N/A
• Average Volume: 7,393 shs
• Market Capitalization: $242.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

GENFIT Stock Analysis - MarketRank™

GENFIT scored higher than 22% of companies evaluated by MarketBeat, and ranked 788th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

GENFIT has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

GENFIT has a consensus price target of $7.00, representing about 44.3% upside from its current price of $4.85.

Amount of Analyst Coverage

GENFIT has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GENFIT are expected to decrease in the coming year, from $0.95 to ($0.57) per share.

Price to Book Value per Share Ratio

GENFIT has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GNFT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GENFIT does not currently pay a dividend.

Dividend Growth

GENFIT does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.75

News Coverage This Week

MarketBeat has tracked 2 news articles for GENFIT this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GENFIT insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.20% of the stock of GENFIT is held by insiders.

Percentage Held by Institutions

2.24% of the stock of GENFIT is held by institutions.

Company Calendar

• Today: 5/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNFT
• CIK: 1757064
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 120
• Year Founded: 1999

Price Target and Rating

• Average Price Target for GENFIT: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +44.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $41.52 million
• Price / Sales: 5.84
• Cash Flow: $0.07 per share
• Price / Cash Flow: 69.34
• Book Value: $1.50 per share
• Price / Book: 3.23

Miscellaneous

• Outstanding Shares: 50,025,000
• Free Float: 47,924,000
• Market Cap: $242.62 million
• Optionable: Not Optionable
• Beta: 1.09